Literature DB >> 23815100

3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.

Xin Hu1, Jaimee R Compton, Mohamed Diwan M Abdulhameed, Charles L Marchand, Kelly L Robertson, Dagmar H Leary, Ajit Jadhav, Jeremy R Hershfield, Anders Wallqvist, Arthur M Friedlander, Patricia M Legler.   

Abstract

In this study, we describe novel inhibitors against Francisella tularensis SchuS4 FabI identified from structure-based in silico screening with integrated molecular dynamics simulations to account for induced fit of a flexible loop crucial for inhibitor binding. Two 3-substituted indoles, 54 and 57, preferentially bound the NAD(+) form of the enzyme and inhibited growth of F. tularensis SchuS4 at concentrations near that of their measured Ki. While 57 was species-specific, 54 showed a broader spectrum of growth inhibition against F. tularensis , Bacillus anthracis , and Staphylococcus aureus . Binding interaction analysis in conjunction with site-directed mutagenesis revealed key residues and elements that contribute to inhibitor binding and species specificity. Mutation of Arg-96, a poorly conserved residue opposite the loop, was unexpectedly found to enhance inhibitor binding in the R96G and R96M variants. This residue may affect the stability and closure of the flexible loop to enhance inhibitor (or substrate) binding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23815100     DOI: 10.1021/jm4001242

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Discovery of novel inhibitors of human galactokinase by virtual screening.

Authors:  Xin Hu; Ya-Qin Zhang; Olivia W Lee; Li Liu; Manshu Tang; Kent Lai; Matthew B Boxer; Matthew D Hall; Min Shen
Journal:  J Comput Aided Mol Des       Date:  2019-02-26       Impact factor: 3.686

2.  Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.

Authors:  Zongyi Hu; Xin Hu; Shanshan He; Hyung Joon Yim; Jingbo Xiao; Manju Swaroop; Cordelle Tanega; Ya-qin Zhang; Guanghui Yi; C Cheng Kao; Juan Marugan; Marc Ferrer; Wei Zheng; Noel Southall; T Jake Liang
Journal:  Antiviral Res       Date:  2015-10-26       Impact factor: 5.970

3.  Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists.

Authors:  Xin Hu; Courtney Myhr; Zaohua Huang; Jingbo Xiao; Elena Barnaeva; Brian A Ho; Irina U Agoulnik; Marc Ferrer; Juan J Marugan; Noel Southall; Alexander I Agoulnik
Journal:  Biochemistry       Date:  2016-03-04       Impact factor: 3.162

4.  Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis.

Authors:  Qiantao Wang; Ramakrishna Edupuganti; Clint D J Tavares; Kevin N Dalby; Pengyu Ren
Journal:  Front Mol Biosci       Date:  2015-03-19

Review 5.  Three-dimensional compound comparison methods and their application in drug discovery.

Authors:  Woong-Hee Shin; Xiaolei Zhu; Mark Gregory Bures; Daisuke Kihara
Journal:  Molecules       Date:  2015-07-16       Impact factor: 4.411

6.  Identification and validation of novel PERK inhibitors.

Authors:  Qiantao Wang; Jihyun Park; Ashwini K Devkota; Eun Jeong Cho; Kevin N Dalby; Pengyu Ren
Journal:  J Chem Inf Model       Date:  2014-05-05       Impact factor: 4.956

7.  Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding.

Authors:  Bill X Huang; Xin Hu; Heung-Sun Kwon; Cheng Fu; Ji-Won Lee; Noel Southall; Juan Marugan; Hee-Yong Kim
Journal:  Commun Biol       Date:  2020-03-06

Review 8.  Hierarchical virtual screening approaches in small molecule drug discovery.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  Methods       Date:  2014-07-27       Impact factor: 3.608

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.